Approved JabWatch summaries of UK GLP-1 pricing, pharmacy availability and consumer guidance. Each article links to its original source.
The Guardian examines how public discussion of changing bodies has intensified alongside the use of Ozempic and increased openness about cosmetic surgery. Eating disorder experts offer guidance on discussing other people’s bodies without causing harm.
Source: The Guardian
NHS spending on GLP-1 weight-loss medicines reached at least £750 million last year, with expenditure on Mounjaro reportedly tripling in 2025. The total was more than twice the funding allocated to the Cancer Drugs Fund.
Source: Daily Mail Health
Orforglipron, a once-daily weight-loss tablet made by the manufacturer of Mounjaro, has been approved for use in the UK by British health officials. Reports say patients taking the medicine lost around two stone in weight, although availability and NHS funding arrangements were not specified.
Source: Daily Mail Health
Researchers have identified a supplement costing about £1.50 a day that may increase the body’s GLP-1 supply and was linked to weight loss over two months. The report compares its results with Wegovy and Mounjaro, but provides no indication that it is approved or available through the NHS as a weight-loss treatment.
Source: Daily Mail Health
The UK has become the first European country to authorise orforglipron for weight management and the treatment of type 2 diabetes, according to the MHRA. The announcement concerns regulatory approval and does not confirm NHS funding or launch pricing.
Source: GOV.UK / MHRA
A new weight-loss pill called Foundayo has been approved for use in the UK. It is made by Eli Lilly, the pharmaceutical company behind the Mounjaro injection.
Source: BBC Health
The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
Source: GOV.UK / MHRA
The MHRA has approved the UK’s first GLP-1 tablet for weight loss. The decision covers its use for weight management, subject to the approved prescribing and safety requirements.
Source: GOV.UK / MHRA